- Eleven Biotherapeutics (EBIO) Q2 results: Revenues: $0.8M (+276.7%); Operating Expenses: $8.8M (+145.6%); Net Loss: ($8.1M) (-78.4%); Loss Per Share: ($0.51) (+85.2%); Quick Assets: $45.0M (+467.0%).
- No financial guidance given.
A closer look at Eleven Bio's Q2 results
Recommended For You
More Trending News
About CARM Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| CARM | - | - |
| Carisma Therapeutics, Inc. | ||